620 related articles for article (PubMed ID: 21216670)
1. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial.
Chollet F; Tardy J; Albucher JF; Thalamas C; Berard E; Lamy C; Bejot Y; Deltour S; Jaillard A; Niclot P; Guillon B; Moulin T; Marque P; Pariente J; Arnaud C; Loubinoux I
Lancet Neurol; 2011 Feb; 10(2):123-30. PubMed ID: 21216670
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial.
EFFECTS Trial Collaboration
Lancet Neurol; 2020 Aug; 19(8):661-669. PubMed ID: 32702335
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial.
AFFINITY Trial Collaboration
Lancet Neurol; 2020 Aug; 19(8):651-660. PubMed ID: 32702334
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of GABA
Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial.
Hess DC; Wechsler LR; Clark WM; Savitz SI; Ford GA; Chiu D; Yavagal DR; Uchino K; Liebeskind DS; Auchus AP; Sen S; Sila CA; Vest JD; Mays RW
Lancet Neurol; 2017 May; 16(5):360-368. PubMed ID: 28320635
[TBL] [Abstract][Full Text] [Related]
7. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
[TBL] [Abstract][Full Text] [Related]
9. Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial.
Gladstone DJ; Danells CJ; Armesto A; McIlroy WE; Staines WR; Graham SJ; Herrmann N; Szalai JP; Black SE;
Stroke; 2006 Jan; 37(1):179-85. PubMed ID: 16322487
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial.
Chamorro A; Amaro S; Castellanos M; Segura T; Arenillas J; Martí-Fábregas J; Gállego J; Krupinski J; Gomis M; Cánovas D; Carné X; Deulofeu R; Román LS; Oleaga L; Torres F; Planas AM;
Lancet Neurol; 2014 May; 13(5):453-60. PubMed ID: 24703208
[TBL] [Abstract][Full Text] [Related]
11. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial.
Asadollahi M; Ramezani M; Khanmoradi Z; Karimialavijeh E
Clin Rehabil; 2018 Aug; 32(8):1069-1075. PubMed ID: 29783900
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.
FOCUS Trial Collaboration
Lancet; 2019 Jan; 393(10168):265-274. PubMed ID: 30528472
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial.
Marquez-Romero JM; Reyes-Martínez M; Huerta-Franco MR; Ruiz-Franco A; Silos H; Arauz A
Clin Neurol Neurosurg; 2020 Mar; 190():105656. PubMed ID: 31896491
[TBL] [Abstract][Full Text] [Related]
15. Fluoxetine for stroke recovery improvement - the doubleblind, randomised placebo-controlled FOCUS-Poland trial.
Bembenek JP; Niewada M; Kłysz B; Mazur A; Kurczych K; Głuszkiewicz M; Członkowska A
Neurol Neurochir Pol; 2020; 54(6):544-551. PubMed ID: 33373036
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine for motor recovery after acute intracerebral hemorrhage (FMRICH): study protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
Marquez-Romero JM; Arauz A; Ruiz-Sandoval JL; Cruz-Estrada Ede L; Huerta-Franco MR; Aguayo-Leytte G; Ruiz-Franco A; Silos H
Trials; 2013 Mar; 14():77. PubMed ID: 23510124
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional, task-specific robot therapy of the arm after stroke: a multicentre, parallel-group randomised trial.
Klamroth-Marganska V; Blanco J; Campen K; Curt A; Dietz V; Ettlin T; Felder M; Fellinghauer B; Guidali M; Kollmar A; Luft A; Nef T; Schuster-Amft C; Stahel W; Riener R
Lancet Neurol; 2014 Feb; 13(2):159-66. PubMed ID: 24382580
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
Gracies JM; Brashear A; Jech R; McAllister P; Banach M; Valkovic P; Walker H; Marciniak C; Deltombe T; Skoromets A; Khatkova S; Edgley S; Gul F; Catus F; De Fer BB; Vilain C; Picaut P;
Lancet Neurol; 2015 Oct; 14(10):992-1001. PubMed ID: 26318836
[TBL] [Abstract][Full Text] [Related]
19. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
20. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.
Hauser RA; Cantillon M; Pourcher E; Micheli F; Mok V; Onofrj M; Huyck S; Wolski K
Lancet Neurol; 2011 Mar; 10(3):221-9. PubMed ID: 21315654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
